Weight Loss Drug Semaglutide Shows Promise in Children Aged 6
A clinical trial found that the weight loss drug Wegovy (semaglutide) significantly reduced BMI in children aged 6 to under 12 with obesity, with nearly 80% achieving a 10% BMI reduction compared to none in the placebo group. The study, which included dietary and exercise support, showed an average BMI decrease of 17.4% over 68 weeks for those on Wegovy. While safety appears comparable to adult studies, long-term effects and sustained weight loss remain under investigation, and regulatory approval for younger children is pending.
הידיעה ב-5 שורות · תקציר של baba
- Wegovy (semaglutide) achieved an average 17.4% BMI reduction in obese children aged 6-12 over 68 weeks.
- Nearly 80% of children on Wegovy saw at least a 10% BMI reduction, versus 0% on placebo.
- The drug's safety profile in children was similar to that seen in adult studies.
- Long-term effects and sustained weight loss after treatment cessation require further study.
- Regulatory approval for Wegovy use in children under 12 is pending.
A recent advanced clinical trial has demonstrated significant results for Wegovy (semaglutide), a weight loss injection already approved for adults and adolescents, when administered to children aged 6 to under 12 who are suffering from obesity. According to data released by the drug's manufacturer, Novo Nordisk, nearly 80% of the children who received the medication achieved at least a 10% reduction in their Body Mass Index (BMI), a stark contrast to the 0% observed in the placebo group. It is important to note that this figure refers to BMI reduction, not necessarily a 10% decrease in overall body weight. The findings from the STEP Young trial are set to be presented at the Obesity Week conference and published in The New England Journal of Medicine. Over 85% of the participating children had severe obesity at the trial's commencement.
The Phase 3 trial involved weekly injections of semaglutide or a placebo. Both groups received a comprehensive support program including a reduced-calorie diet and increased physical activity, ensuring the study measured the drug's added benefit. After 68 weeks, the Wegovy group experienced an average BMI reduction of 17.4%, while the placebo group saw a slight increase of 2.2%. Any degree of BMI reduction was observed in 83% of children on Wegovy, compared to 23.5% in the placebo group. Furthermore, one analysis indicated that 38.4% of children in the Wegovy group dropped below the obesity threshold, versus 2.1% in the placebo group. However, falling below the obesity threshold does not guarantee a return to a healthy weight range or sustained results after treatment cessation.
Novo Nordisk reported that the drug's safety profile in this trial was consistent with previous studies on semaglutide, with no unexpected findings regarding growth or sexual development. Nevertheless, the current trial duration does not fully address the effects of long-term treatment in children or the durability of weight loss after discontinuing the medication. In Israel, Wegovy's current approved indication for obesity in adolescents begins at age 12 under specific conditions. The results for younger children do not automatically grant approval for this age group, and further regulatory authorization is pending for its use in younger populations.
אותו אירוע, כפי שכל מערכת דיווחה עליו בנפרד. פתחו כמה דיווחים כדי להשוות מה כל מערכת מדגישה, ומה היא משאירה בחוץ.
מרכז 2ימין 2
לא אותו אירוע: ידיעות אחרות שחולקות עם הידיעה הזו אנשים, מקומות או נושא. רקע, תגובות והמשכים.
